10/069681



PATENT COOPERATION TREATY PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

International application No.	Applicant's or agent's file reference	FOR FURTHER see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.				
PCT/EP 00/ 08048	ACC/P32396	ACTION				
Applicant SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES This International Search Report has been prepared by this International Bureau. This International Search Report consists of a total of	International application No.	International filing date (day/month/year) (Earliest) Priority Date (day/month/year)				
This international Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau. This International Search Report consists of a total of	PCT/EP 00/08048	17/08/2000	20/08/1999			
This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau. This International Search Report consists of a total of	Applicant					
This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau. This International Search Report consists of a total of						
This International Search Report consists of a total of	SMITHKLINE BEECHAM LABORA	TOIRES PHARMACEUTIQUES				
This International Search Report consists of a total of						
This International Search Report consists of a total of3sheets. It is also accompanied by a copy of each prior art document cited in this report. It is also accompanied by a copy of each prior art document cited in this report. With regard to the language, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item. the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)). With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international application in written form. was carried out on the basis of the sequence listing: contained in the international application in written form. filed together with the international application in computer readable form. furnished subsequently to this Authority in written form. turnished subsequently to this Authority in computer readable form. the statement that the subsequently turnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished. the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished. Unity of Invention Is lacking (see Box II). Unity of Invention Is lacking (see Box II). With regard to the title,			ority and is transmitted to the applicant			
It is also accompanied by a copy of each prior and document cited in this report. 1. Basis of the report a. With regard to the language, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item. the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)). With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing: contained in the international application in written form. filed together with the international application in computer readable form. furnished subsequently to this Authority in written form. furnished subsequently to this Authority in computer readable form. the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished. the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished. The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished. With regard to the title,	according to Article 16. A copy is being tra	ansmitted to the international buread.				
It is also accompanied by a copy of each prior and document cited in this report. 1. Basis of the report a. With regard to the language, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item. the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)). With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing: contained in the international application in written form. filed together with the international application in computer readable form. furnished subsequently to this Authority in written form. furnished subsequently to this Authority in computer readable form. the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished. the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished. The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished. With regard to the title,	This International Search Report consists	of a total of sheets.				
a. With regard to the language, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item. the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)). b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing: contained in the international application in written form. filed together with the international application in computer readable form. furnished subsequently to this Authority in written form. the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished. the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished. Certain claims were found unsearchable (See Box I). Unity of Invention is lacking (see Box II). With regard to the title, the text is approved as submitted by the applicant. The text has been established by this Authority to read as follows: PHARMACEUTICAL FORMULATION COMPRISING AMOXYCILLIN AND CLAVULANATE 5. With regard to the abstract, The figure of the drawings to be published with the abstract is Figure No. as suggested by the applicant. With ore of the drawings to be published with the abstract is Figure No. as suggested by the applicant. None of the figures.			report.			
a. With regard to the language, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item. the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)). b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing: contained in the international application in written form. filed together with the international application in computer readable form. furnished subsequently to this Authority in written form. the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished. the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished. Certain claims were found unsearchable (See Box I). Unity of Invention is lacking (see Box II). With regard to the title, the text is approved as submitted by the applicant. The text has been established by this Authority to read as follows: PHARMACEUTICAL FORMULATION COMPRISING AMOXYCILLIN AND CLAVULANATE 5. With regard to the abstract, The figure of the drawings to be published with the abstract is Figure No. as suggested by the applicant. With ore of the drawings to be published with the abstract is Figure No. as suggested by the applicant. None of the figures.	1 Recip of the report		-			
the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)). b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing: contained in the international application in written form. filed together with the international application in computer readable form. furnished subsequently to this Authority in written form. furnished subsequently to this Authority in computer readable form. the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished. the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished. Certain claims were found unsearchable (See Box I). Unity of Invention is lacking (see Box II). With regard to the title, the text is approved as submitted by the applicant. The text has been established by this Authority to read as follows: PHARMACEUTICAL FORMULATION COMPRISING AMOXYCILLIN AND CLAVULANATE 5. With regard to the abstract, The text is approved as submitted by the applicant. the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority. 6. The figure of the drawings to be published with the abstract is Figure No. as suggested by the applicant. because the applicant failed to suggest a figure.	•	international search was carried out on the bas	is of the international application in the			
b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing: contained in the international application in written form. lited together with the international application in computer readable form. furnished subsequently to this Authority in written form. furnished subsequently to this Authority in computer readable form. furnished subsequently to this Authority in computer readable form. the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished. the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished. Certain claims were found unsearchable (See Box I). Unity of Invention Is lacking (see Box II). With regard to the title, the text is approved as submitted by the applicant. X the text has been established by this Authority to read as follows: PHARMACEUTICAL FORMULATION COMPRISING AMOXYCILLIN AND CLAVULANATE With regard to the abstract, The text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority. The figure of the drawings to be published with the abstract is Figure No. as suggested by the applicant. None of the figures.	language in which it was filed, unl	ess otherwise indicated under this item.				
b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing: contained in the international application in written form. filled together with the international application in computer readable form. furnished subsequently to this Authority in written form. furnished subsequently to this Authority in computer readable form. the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filled has been furnished. the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished. Certain claims were found unsearchable (See Box I). Unity of Invention is tacking (see Box II). With regard to the title, the text is approved as submitted by the applicant. The text has been established by this Authority to read as follows: PHARMACEUTICAL FORMULATION COMPRISING AMOXYCILLIN AND CLAVULANATE 5. With regard to the abstract, the text is approved as submitted by the applicant. the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority. The figure of the drawings to be published with the abstract is Figure No. as suggested by the applicant. None of the figures.		as carried out on the basis of a translation of th	ne international application furnished to this			
was carried out on the basis of the sequence listing:	b. With regard to any nucleotide an	d/or amino acid sequence disclosed in the in	ternational application, the international search			
filed together with the international application in computer readable form. furnished subsequently to this Authority in written form. furnished subsequently to this Authority in computer readable form. the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished. Certain claims were found unsearchable (See Box I). Certain claims were found unsearchable (See Box I). Unity of Invention is lacking (see Box II). With regard to the title, the text is approved as submitted by the applicant. the text has been established by this Authority to read as follows: PHARMACEUTICAL FORMULATION COMPRISING AMOXYCILLIN AND CLAVULANATE With regard to the abstract, The text is approved as submitted by the applicant. the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority. The figure of the drawings to be published with the abstract is Figure No. as suggested by the applicant. None of the figures.	was carried out on the basis of the	e sequence listing:				
furnished subsequently to this Authority in written form. furnished subsequently to this Authority in computer readble form. the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished. the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished. Certain claims were found unsearchable (See Box I). Unity of Invention is lacking (see Box II). With regard to the title, the text is approved as submitted by the applicant. It he text has been established by this Authority to read as follows: PHARMACEUTICAL FORMULATION COMPRISING AMOXYCILLIN AND CLAVULANATE With regard to the abstract, The text is approved as submitted by the applicant. the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority. The figure of the drawings to be published with the abstract is Figure No. as suggested by the applicant. Some of the figures. None of the figures.		• •	1			
furnished subsequently to this Authority in computer readble form. the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished. the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished. Certain claims were found unsearchable (See Box I). Unity of Invention is lacking (see Box II). With regard to the title, the text is approved as submitted by the applicant. X the text has been established by this Authority to read as follows: PHARMACEUTICAL FORMULATION COMPRISING AMOXYCILLIN AND CLAVULANATE With regard to the abstract, X the text is approved as submitted by the applicant. the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority. The figure of the drawings to be published with the abstract is Figure No. as suggested by the applicant. None of the figures. None of the figures.			•			
international application as filed has been furnished. the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished 2.		•				
the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished Certain claims were found unsearchable (See Box I). Unity of Invention is lacking (see Box II). With regard to the title, the text is approved as submitted by the applicant. X the text has been established by this Authority to read as follows: PHARMACEUTICAL FORMULATION COMPRISING AMOXYCILLIN AND CLAVULANATE With regard to the abstract, the text is approved as submitted by the applicant. the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority. The figure of the drawings to be published with the abstract is Figure No. as suggested by the applicant. None of the figures.			pes not go beyond the disclosure in the			
4. With regard to the title, the text is approved as submitted by the applicant. The text has been established by this Authority to read as follows: PHARMACEUTICAL FORMULATION COMPRISING AMOXYCILLIN AND CLAVULANATE 5. With regard to the abstract, The text is approved as submitted by the applicant. the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority. 6. The figure of the drawings to be published with the abstract is Figure No. as suggested by the applicant. Decause the applicant failed to suggest a figure.	the statement that the info		identical to the written sequence listing has been			
4. With regard to the title, the text is approved as submitted by the applicant. The text has been established by this Authority to read as follows: PHARMACEUTICAL FORMULATION COMPRISING AMOXYCILLIN AND CLAVULANATE 5. With regard to the abstract, The text is approved as submitted by the applicant. the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority. 6. The figure of the drawings to be published with the abstract is Figure No. as suggested by the applicant. Decause the applicant failed to suggest a figure.	2 Certain claims were four	nd unsearchable (See Roy I)				
4. With regard to the title, the text is approved as submitted by the applicant. X the text has been established by this Authority to read as follows: PHARMACEUTICAL FORMULATION COMPRISING AMOXYCILLIN AND CLAVULANATE 5. With regard to the abstract, X the text is approved as submitted by the applicant. the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority. 6. The figure of the drawlngs to be published with the abstract is Figure No. as suggested by the applicant. Decause the applicant failed to suggest a figure.	لمسل	,				
the text is approved as submitted by the applicant. X the text has been established by this Authority to read as follows: PHARMACEUTICAL FORMULATION COMPRISING AMOXYCILLIN AND CLAVULANATE 5. With regard to the abstract, X the text is approved as submitted by the applicant. the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority. 6. The figure of the drawlngs to be published with the abstract is Figure No. as suggested by the applicant. Decause the applicant failed to suggest a figure.		,	. ,			
the text has been established by this Authority to read as follows: PHARMACEUTICAL FORMULATION COMPRISING AMOXYCILLIN AND CLAVULANATE 5. With regard to the abstract, X	4. With regard to the title,					
PHARMACEUTICAL FORMULATION COMPRISING AMOXYCILLIN AND CLAVULANATE 5. With regard to the abstract, The text is approved as submitted by the applicant. the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority. 6. The figure of the drawlngs to be published with the abstract is Figure No. as suggested by the applicant. Decause the applicant failed to suggest a figure.		* ''				
5. With regard to the abstract, The text is approved as submitted by the applicant. the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority. 6. The figure of the drawlngs to be published with the abstract is Figure No. as suggested by the applicant. because the applicant failed to suggest a figure.	_		AND CLAVIII ANATE			
the text is approved as submitted by the applicant. the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority. 6. The figure of the drawlngs to be published with the abstract is Figure No. as suggested by the applicant. because the applicant failed to suggest a figure.	PHARMACEUTICAL FURMULA	TION COMPRISING AMOXICILLIN	AND CLAVULANATE			
the text is approved as submitted by the applicant. the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority. 6. The figure of the drawings to be published with the abstract is Figure No. as suggested by the applicant. because the applicant failed to suggest a figure.						
the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority. 6. The figure of the drawlngs to be published with the abstract is Figure No. as suggested by the applicant. because the applicant failed to suggest a figure.	5. With regard to the abstract,					
within one month from the date of mailing of this international search report, submit comments to this Authority. 6. The figure of the drawlngs to be published with the abstract is Figure No. as suggested by the applicant. because the applicant failed to suggest a figure.		• • • • • • • • • • • • • • • • • • • •				
6. The figure of the drawings to be published with the abstract is Figure No. as suggested by the applicant. because the applicant failed to suggest a figure.	the text has been establish within one month from the	hed, according to Rule 38.2(b), by this Authority date of mailing of this international search rep	y as it appears in Box III. The applicant may, ort, submit comments to this Authority.			
as suggested by the applicant. None of the figures.						
because the applicant failed to suggest a figure.			None of the figures.			
because this figure better characterizes the invention.	= =					
	because this figure better	characterizes the invention.				

INTERNATIONAL SEARCH REPORT

International Application No EP 00/08048

a. classification of subject matter IPC 7 A61K9/00 A61K31/43

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 35672 A (SANROMA BORDALLO JOSE LUIS; SMITHKLINE BEECHAM S A (ES); MENTION J) 20 August 1998 (1998-08-20) cited in the application page 3, line 30 -page 4, line 4 page 4, line 18 - line 34 page 5, line 31 -page 6, line 3 page 6, line 20 - line 35	1,2,4, 8-10,13
A	page 12, line 28 -page 13, line 3; claims 1-8,11; examples 8,9/	3,5-7, 11,12, 14,15

X Further documents are listed in the continuation of box C.	Patent family members are listed in annex.		
 Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed 	 "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. 		
Date of the actual completion of the international search	"&" document member of the same patent family Date of mailing of the international search report		
7 November 2000	15/11/2000		
Name and mailing address of the ISA	Authorized officer		
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Marttin, E		

INTERNATIONAL SEARCH REPORT

International	Application No
(EP	00/08048

C.(Continu	ation) DOCUMENTS CONSIDENCE TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 00 03695 A (LEK TOVARNA FARMACEVTSKIH; KOFLER BOJAN (SI); KOVACIC MATEJA (SI)) 27 January 2000 (2000-01-27) page 1, paragraph 1 page 2, last paragraph -page 3, paragraph 1 page 4, line 14 - line 22 page 5, paragraph 1 - paragraph 2; claims 1,2; examples 1,2	1,4,8,9
4	EP 0 389 177 A (BEECHAM GROUP PLC) 26 September 1990 (1990-09-26) page 2, line 24 - line 26 page 2, line 40 - line 41; claims 1,9,10; example 2	1-15
		·

1

INTERNATIONAL SEARCH REPORT

Information on patent family members

l:	nternational	Application No
	EP	00/08048
mily		Publication

	tent document in search report		Publication date		ratent family member(s)	Publication date
WO	9835672	A	20-08-1998	AU BG BR CN EP NO PL	6719698 A 103664 A 9807383 A 1251990 T 0975342 A 993887 A 334976 A	08-09-1998 31-03-2000 14-03-2000 03-05-2000 02-02-2000 12-08-1999 27-03-2000
WO	0003695	Α	27-01-2000	AU	5049799 A	07-02-2000
EP	0389177	Α	26-09-1990	US AU AU CA JP NZ PT ZA	5114929 A 626649 B 5147690 A 2012492 A 2300115 A 232979 A 93497 A 9002089 A	19-05-1992 06-08-1992 27-09-1990 21-09-1990 12-12-1990 26-05-1992 07-11-1990 27-03-1991